Stanford researchers have discovered a breakthrough technology that shrinks and removes blood clots to treat strokes, heart ...

Coronary thrombosis and pulmonary thromboembolism are common causes of cardiac arrest. We assessed whether the administration of tissue plasminogen activator (t-PA) during cardiopulmonary resuscita ...

Recombinant tissue plasminogen activator (rtPA) or alteplase has been approved in the USA since 1996 for treatment of acute stroke, and in the EU since 2002, for use within a 3-h time window ...

Tissue plasminogen activator (tPA) is a medication that doctors administer following a stroke caused by a blood clot. It breaks up the blood clot to allow blood flow to return to the brain.

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global tissue plasminogen activator market is estimated to be valued at US$ 2,455.4 million in 2020 and is expected to exhibit ...

In 1991, research nurse Karen Rapp was hired by the UC San Diego Stroke Center to oversee a new clinical trial. The goal: to ...

A team of scientists from the University of Colorado, Boulder just published an article, "The non-nutritive sweetener ...

NEW YORK — Vitrectomy using balanced saline solution without tissue plasminogen activator is effective for displacement of thick submacular hemorrhage, according to a speaker here. “As you all ...

Older Black patients on Medicare in the United States experience disparities in stroke care access and outcomes, compared with White patients.

Emergency treatment with a blood clot buster called tissue plasminogen activator for a patient who had a stroke while being treated with the experimental Alzheimer's drug lecanemab led to a fatal ...